Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview - First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million - First quarter DAYBUE™ (trofinetide) net product sales of $75.9 million SAN DIEGO, CA, May 8, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024. “In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% re ...

Industry Overview - The earnings season for the drug/biotech sector is concluding, with companies like Viatris and Perrigo set to report their first-quarter 2024 results this week [1] - 55% of companies in the Medical sector have reported quarterly earnings, with 93.9% beating earnings estimates and 75.8% exceeding revenue estimates [1] - Despite a year-over-year earnings decline of 31.2%, revenues in the Medical sector rose by 4.4% [1] Company Summaries Viatris - Viatris has a mixed performance history, beating earnings expectations in three of the last four quarters, with an average positive earnings surprise of 3.78% [3] - The company has an Earnings ESP of +0.74% and a Zacks Rank of 3, indicating a likely positive surprise, with consensus estimates of 68 cents per share in earnings and $3.74 billion in revenue [3] - Revenues in the Generic segment are expected to improve due to new products, offsetting declines in mature products [4] Perrigo Company - Perrigo has also shown mixed results, beating earnings expectations in three of the last four quarters, with an average beat of 6.47% [5] - The company has an Earnings ESP of 0.00% and a Zacks Rank of 4, with consensus estimates of 24 cents per share in earnings and $1.09 billion in revenue [5] - Sales in the Consumer Self Care Americas segment may be negatively impacted by lower net product sales in the U.S., while the Consumer Self Care International segment could benefit from acquisitions [5] Teva Pharmaceutical - Teva has a mixed earnings history, beating estimates in two of the last four quarters, with a trailing four-quarter average negative earnings surprise of 1.80% [7] - The company has an Earnings ESP of -4.46% and a Zacks Rank of 3, with consensus estimates of 51 cents per share in earnings and $3.7 billion in revenue [7] - Revenue growth is expected to be driven by higher sales of Austedo, despite lower sales from legacy brands [7] Iovance Biotherapeutics - Iovance has a mixed track record, beating estimates in two of the last four quarters, with an average beat of 20.05% [8] - The company has an Earnings ESP of 0.00% and a Zacks Rank of 3, with consensus estimates indicating a loss of 45 cents per share and $2.9 million in revenue [8] - Investors will be looking for updates on the commercial launch of its new melanoma drug, Amtagvi, during the earnings call [8] ACADIA Pharmaceuticals - ACADIA has a mixed earnings history, with an average earnings surprise of 18.56% over the last four quarters [9] - The company has an Earnings ESP of -71.34% and a Zacks Rank of 3, with consensus estimates of 17 cents per share in earnings and $206.9 million in revenue [9]

There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures. Several major pharmaceutical firms are grappling with patent cliffs, where key drug exclusivities are expiring. This opens the door for generic competition.Moreover, with the broader market presenting attractive investment options, holding on to these riskier pharma plays could result in significant opportunity cost. Many promising growth ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is ...

Key TakeawaysAcadia Pharmaceuticals' drug missed endpoints for treating schizophrenia patients, news that sent Acadia shares sharply lower.The drug maker was looking at the potential use of its current Parkinson's psychosis medicine, Nuplazid.Acadia said it would not hold any more clinical trials for Nuplazid.Shares in Acadia were down more than 16% in late-afternoon trading. Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expa ...

Acadia Pharmaceuticals Inc. (ACAD) shares lost 15% in the after-market hours on Mar 11, after the company announced the failure of its late-stage study evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.In the phase III ADVANCE-2 study, treatment with pimavanserin did not achieve statistical significance in demonstrating improvement over placebo on the study’s primary endpoint of change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score. The NSA- ...

Core Insights - Acadia Pharmaceuticals' stock is declining following the failure of its Phase 3 clinical trial for pimavanserin, a drug aimed at treating negative symptoms of schizophrenia [1][2] - The trial did not meet its primary endpoint, leading the company to halt further development of pimavanserin [1] - As a result of the trial's failure, ACAD stock has dropped by 17.6% [2] Company Overview - Acadia Pharmaceuticals is focused on developing treatments for central nervous system disorders, with pimavanserin being a key candidate for schizophrenia [1] - The CEO expressed disappointment over the trial results, highlighting the significant unmet need in the patient population [1] Market Reaction - The failure of the Phase 3 trial has resulted in negative sentiment among shareholders, as the company cannot seek commercialization approval for pimavanserin [2] - The stock market response reflects investor concerns regarding wasted resources in drug development that will not yield a marketable product [2]

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07). The safety and tolerability profi ...

Group 1 - Acadia Pharmaceuticals will participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024, at 11:10 a.m. Eastern Time [1] - A live webcast of the presentation will be available on Acadia's website, with an archived recording accessible for approximately one month after the event [1] Group 2 - Acadia Pharmaceuticals has been advancing breakthroughs in neuroscience for 30 years, focusing on vital solutions for patients [2] - The company developed the first and only FDA-approved drug for treating hallucinations and delusions associated with Parkinson's disease psychosis, as well as the first FDA-approved drug for Rett syndrome [2] - Current clinical-stage development efforts are aimed at addressing negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in central nervous system disorders [2]

Acadia Pharmaceuticals Inc. (ACAD) reported fourth-quarter 2023 earnings of 28 cents per share, missing the Zacks Consensus Estimate of 32 cents. In the year-ago quarter, the company had incurred a loss of 26 cents per share.The bottom line improved year over year owing to higher product sales.The company recorded total revenues of $231 million in the fourth quarter, surpassing the Zacks Consensus Estimate of $223 million. Acadia’s net product revenues comprise revenues generated from the sale of its two ma ...